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Penile squamous cell carcinoma (PSCC) accounts for over 95% of penile malignancies and
causes significant mortality and morbidity in developing countries. Molecular mechanisms
and therapies of PSCC are understudied, owing to scarcity of laboratory models. Herein, we
describe a genetically engineered mouse model of PSCC, by co-deletion of Smad4 and Apc in
the androgen-responsive epithelium of the penis. Mouse PSCC fosters an immunosuppres-
sive microenvironment with myeloid-derived suppressor cells (MDSCs) as a dominant
population. Preclinical trials in the model demonstrate synergistic efficacy of immune
checkpoint blockade with the MDSC-diminishing drugs cabozantinib or celecoxib. A critical
clinical problem of PSCC is chemoresistance to cisplatin, which is induced by Pten deficiency
on the backdrop of Smad4/Apc co-deletion. Drug screen studies informed by targeted pro-
teomics identify a few potential therapeutic strategies for PSCC. Our studies have established
what we believe to be essential resources for studying PSCC biology and developing ther-
apeutic strategies.
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Penile cancer can constitute up to 10% of male malignanciesin some African, Asian and South American areas1. Whileit represents ~0.5% of all cancers among men in the United
States and other developed countries, penile cancer often results
in devastating disfigurement and only half of the patients survive
beyond 5 years1. PSCC accounts for over 95% of penile malig-
nancies1. Risk factors associated with PSCC incidence include the
absence of neonatal circumcision, phimosis, chronic inflamma-
tion, poor hygiene, tobacco use, and infection with human
papillomavirus (HPV)2. A recent large meta-analysis reports a
pooled HPV prevalence of 50.8% in penile cancer3. HPV infec-
tion is more common in carcinomas in situ than in invasive
forms4, and the presence of high‐risk HPV confers a survival
advantage in patients with PSCC5. It is possible that HPV-
positive and HPV-negative PSCC develop through certain con-
vergent mechanisms, which may be leveraged for therapies.
Expression alterations for some genes have been documented in
PSCC, such as RAS, MYC, EGFR, E-cadherin, COX2, IGF1R, and
MMP2/96. However, the precise molecular mechanisms govern-
ing PSCC initiation and progression remains elusive, mainly due
to the shortage of experimental tools. Recently, a number of
PSCC cell lines have been developed7–9. However, the generation
of genetically engineered mouse (GEM) models of PSCC has not
been reported.
Standard treatment regimens for penile cancer are limited to
surgery, radiation, and chemotherapy1,10,11. The mainstay of sys-
temic therapy for advanced PSCC is cisplatin-based chemotherapy,
with average response rates between 15 to 55% and median overall
survival (OS) ranging between 5 and 12 months1,10–12. Patients
whose PSCC progresses or recurs after front-line cisplatin-based
chemotherapy experience poor responses to salvage treatments
(OS < 6 months)13. Therefore, there is an urgent need to identify
molecular mechanisms for chemoresistance of PSCC and seek
other approaches for metastatic PSCC. Immunotherapy using
immune checkpoint blockade (ICB), such as anti-CTLA4 and anti-
PD1 antibodies, has revolutionized cancer treatment and has
generated durable therapeutic responses in a significant subset of
patients across a variety of cancer types. Currently clinical trials are
recruiting patients to assess the role of ICB agents in penile cancer
specifically or a rare tumor cohort that includes penile cancer.
Examples include pembrolizumab for advanced PSCC
(NCT02837042) and ipilimumab plus nivolumab for advanced rare
tumors including penile cancer (NCT03333616, NCT02834013).
Developing resources for PSCC such as GEM models will be cri-
tical to evaluate the efficacy of ICB in a meaningful preclinical
setting and, perhaps more importantly, to predict potential resis-
tance mechanisms for ICB and design corresponding combination
therapy strategies.
Here, we report the generation and characterization of two
GEM models of PSCC through the manipulation of signaling
pathways relevant to HPV carcinogenesis mechanisms and clin-
ical evidence of PSCC. The murine PSCC displays strong immune
gene signatures and infiltration, consistent with clinical evidence
gathered by bioinformatics analysis and immunohistochemistry
validation. Intratumoral immunosuppressive myeloid cell infil-
tration suggests the benefit of combining targeted therapy and
immunotherapy to achieve maximal clinical efficacy. This illu-
minates a testable clinical trial hypothesis for combination ther-
apy in the treatment of lethal PSCC.
Results
Establishment of genetically engineered mouse model of PSCC.
Androgen receptor (AR) is expressed in the epithelium of the
developing human fetal penis14. We stained human primary
penile tumor samples (n= 8, Supplementary Table 1) and
observed pronounced nuclear AR expression in adjacent normal
epithelium (5/5 cases) but not in the malignant area (8/8 cases,
Fig. 1a). There is also persistent AR expression in the rodent
penis15, which we further confirmed in the penis of wild type
adult male mice (Fig. 1b). This result prompted us to hypothesize
that a GEM model employing an AR-responsive Cre driver in
conjunction with LoxP alleles of tumor suppressor genes with
relevance to human penile cancer could form penile cancer in
mice. The Cre-expressing line PB-Cre4 carries the Cre gene under
the control of a strong AR-responsive promoter and is frequently
used to manipulate gene expression in the mouse prostate16. To
determine if PB-Cre4 drives recombination of mouse penile
epithelium, we crossed PB-Cre4 to the fluorescence reporter allele
mTmG17 and the penis clearly showed GFP expression in the
epithelium (Fig. 1c and Supplementary Fig. 1a). AR+ nuclei
overlapped with GFP+ epithelial cells (Supplementary Fig. 1b).
To examine genetic changes that may cause penile tumorigenesis,
we analyzed several previously developed prostate tumor models
that used PB-Cre4, including Pten18, Pten Smad419, and Pten p53
Smad420. Normal histology of the penile epithelium was observed
for these mice even at the age when they succumbed to the
prostate tumor burden (Supplementary Fig. 1c), indicating loss of
function for Pten, p53 or Smad4 (individually or in combination)
is insufficient to drive penile tumorigenesis.
Next, we focused on two pathways, Wnt/Apc/β-catenin and
TGFβ/Smad pathways, based on their relevance to oncogenic
HPV. Oncogenic HPV encodes two oncoproteins E6 and E7,
which bind and facilitate degradation of p53 and Rb, respec-
tively21. While E6 and E7 can immortalize cells in vitro, they are
not sufficient for tumor development in vivo21, suggesting that
additional mechanisms are necessary for tumor initiation. E6
binds to cellular partner E6AP to stabilize β-catenin and stimulate
Wnt signaling22, and knockdown of E6 and E7 expression
induces a substantial reduction of nuclear β-catenin and TCF
transcriptional activity23. E7 blocks TGF-β induced transcription
and growth inhibition by directly binding to Smad3 and Smad4
thus interfering with their interaction24. E6 has a similar
activity25. To recapitulate these signaling effects from E6/E7, we
reasoned that Wnt/β-catenin activation and TGFβ/Smad pathway
inactivation in the mouse penile epithelium might lead to penile
tumorigenesis. We used conditional null alleles of Apc and Smad4
to test our hypothesis. PB-Cre4+ Smad4L/L mice had no prostate
lesion20, nor did we observe them to show any abnormality of the
penis (Supplementary Fig. 1d). PB-Cre4+ ApcL/L mice developed
prostate hyperplasia with squamous metaplasia as early as
7 months of age26, and the penis of these mice was normal at
3.5 months of age but displayed mild dysplasia with hyperker-
atosis at 12.5 months of age (Fig. 1d and Supplementary Fig. 1d).
The epidermal layer was moderately multiplied, yet no SCC
pathology was found (Supplementary Fig. 1d). Penile prolapse
(paraphimosis) is a condition in which the penis no longer
retracts back into the prepuce, and can be used as a sign to
indicate penile tumor formation in mice. In total, 0/19 PB-Cre4+
Smad4L/L mice and 1/18 PB-Cre4+ ApcL/L mice exhibited penile
prolapse (Fig. 1e). The only prolapsed penis of a PB-Cre4+ ApcL/L
mouse was caused by excessive keratinization. Remarkably, when
Smad4 and Apc were co-deleted, PB-Cre4+ Smad4L/L ApcL/L mice
(SA genotype) developed penile prolapse at 100% penetrance
(Fig. 1e). When crossed to mTmG allele (SAm genotype), GFP+
solid tumor nodules formed in mouse penis (Fig. 1f). At the
histological level, the tumors contain conspicuous keratin pearls,
which are pathognomonic for SCC (Fig. 1g). We noted that, by
the time the penile tumors formed in these mice (median
17.2 weeks), the prostate remained normal (Fig. 1h). Given the
AR expression by normal penile epithelium (Fig. 1b), we
determined whether AR signaling was required to sustain SA
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Fig. 1 Smad4 and Apc co-deletion leads to penile squamous cell carcinoma in mice. a, b IHC stain for AR in human penile tumors (n= 8) and normal
mouse penis (n= 5). Scale bar 100 μm. c, d Morphology and fluorescence for resected mouse penises of indicated genotype and age. Scale bar 2 mm. e
Penile prolapse free survival curves for mice of three genotypes with n indicated. ****P < 0.0001, log-rank test. fMorphology and fluorescence for resected
mouse penis of SAm genotype at 6.4 months of age, with GFP+ tumor nodules clearly visible. Scale bar 2 mm. g, h H&E stain of penis and prostate lobes
(anterior AP, dorsolateral DLP) of SA mouse at 6.8 month of age. White arrows denote keratin pearls. Scale bar 100 μm. i SA males at 8–12 weeks
underwent castration or mock surgical procedure. After 4 weeks, the mice were euthanized. The serum testosterone was measured with ELISA for the mice
and age-matched wild type (WT) males were used as control (n= 6 for each group). j Representative images of the mouse penis at each week post-
surgery. k, l Weight, representative image and H&E staining of resected penises from WT control or SA mice 4 weeks post-surgery. Scale bar 10 mm and
200 μm (n= 8 for WT, n= 6 for mock and castration). In i, k, data represent mean ± SD. #P > 0.05, ***P < 0.001, ****P < 0.0001, two-sided Student’s t test.
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penile tumor growth by performing mock procedure or surgical
castration on 8–12-week-old SA males and following the penile
tumor progression for 4 weeks. Castration depleted serum
testosterone level (Fig. 1i), yet elicited undetectable effect on
penile tumor growth (Fig. 1j–k), histology (Fig. 1l), proliferation
marker Ki67, or apoptosis marker cleaved caspase-3 (Supple-
mentary Fig. 1e). We conclude that AR signaling is dispensable
for sustaining PSCC. In summary, the first GEM model of PSCC
was developed by co-deleting Apc and Smad4 in the penile
epithelium.
Transcriptomic analysis of mouse penile cancer. To identify
differentially expressed genes between normal and cancerous
mouse penis, we performed RNA-seq on penile tumors from 5-
month-old SA mice and penile epithelium from age-matched wild
type (WT) mice. Significant genes were defined by using a cut-off
of 0.01 on the Benjamini-Hochberg corrected P-value and an
absolute log2(fold change) value of at least 2 (i.e. fold change ≥ 4).
We detected a total of 1660 significantly upregulated genes and
642 downregulated genes in SA compared with the WT penis
(Fig. 2a, Supplementary Fig. 2a, and Supplementary Table 2). To
identify significantly enriched pathways by SA tumors, Ingenuity
Pathway Analysis (IPA) was used to analyze the differentially
expressed genes and identified 102 Ingenuity Canonical Pathways
with P-value < 0.05 (Supplementary Table 3). Of note, the top
ranked two pathways are Granulocyte Adhesion and Diapedesis
and Agranulocyte Adhesion and Diapedesis, because of upregu-
lation of many cytokines and cytokine receptors suggestive of an
inflammatory phenotype (Supplementary Table 4). Matrix
Metalloproteases and Eicosanoid Signaling were significantly
enriched (Supplementary Tables 3 and 4), underscoring the
invasive SCC histology and supporting the inflammation of SA
tumors. Both Wnt/β-catenin Signaling and FGF Signaling were
hyperactivated in SA tumors as a result of genetic loss of Apc and
dramatically enhanced expression of FGF ligands, respectively
(Supplementary Tables 3 and 4). IPA can provide analyses to
identify putative upstream regulators to account for gene
expression changes, which listed β-catenin as the top putative
upstream regulator (Supplementary Table 5). Massive transcrip-
tional regulation by β-catenin complex (Fig. 2b) was expected
because of Apc loss, with confirmed nuclear concentration in SA
tumors compared with WT penis (Fig. 2c). Enhanced β-catenin
localization in the nucleus and cytoplasma was also validated in
about one third of human PSCC samples using tissue array
analysis (n= 191 total, Supplementary Figs. 2b, c). Two of β-
catenin transcriptional targets, Sox2 and Ptgs2, were upregulated
by 137-fold and 9-fold respectively at the RNA level. Sox2 was
shown to be a master regulator for cancer stem cells in skin
SCC27. Ptgs2, better known as Cox2, converts arachidonic acid to
prostaglandins, which in turn induce inflammatory reactions.
Significant upregulation of Sox2 and Cox2 in SA tumors at the
protein level was confirmed by immunohistochemistry (IHC)
(Figs. 2d, e). By a separate algorithm in IPA to estimate master
regulators to explain transcriptomic changes and pathway
enrichment, Cox2 was identified as the top regulator to account
for cytokine upregulation and the phenotype Adhesion of
immune cells (Fig. 2f and Supplementary Table 6). COX2 upre-
gulation is highly relevant to PSCC as previously shown28.
Western blot further confirmed upregulation of Cox2 and Sox2 in
SA tumors relative to penile tissues from WT and PB-Cre4+
Smad4L/L mice (Fig. 2g). At the protein level, we also detected
upregulated cyclin D1 and phospho-Rb (Ser780) signals in SA
tumors (Fig. 2g). Intensified cyclin D1 expression is expected
given its known regulation by Smad420 and β-catenin/LEF1
complex29. Cyclin D1 overexpression and correlated Ki67
expression was reported in PSCC30 and confirmed in our model
(Fig. 2h). Using a penile cancer cell line, SA1, established from an
SA penile tumor, we generated shRNA-mediated Sox2 knock-
down (Fig. 2i), which attenuated subcutaneous tumor growth of
SA1 (Fig. 2j–l). Together, transcriptomic profiling revealed
extensive signaling changes associated with PSCC formation in
mice and, in particular, signaling molecules involved in inflam-
mation and immunity.
Infiltration of immunosuppressive myeloid cells. Transcrip-
tional profiling suggests massive immune response in the SA
penile tumors. To examine the immune infiltration, we dis-
sociated penile tumors from 4–5 month-old SA mice and normal
penile epithelium from Cre- littermates, and catalogued the
intratumoral immunocytes by mass cytometry (CyTOF) using a
35-antibody panel31. Consistent with the enrichment of various
immune-related signaling pathways, there was a 7-fold increase of
CD45+ immune cells (as fraction of all live cells) in mouse PSCC
compared with normal penis (Fig. 3a). When quantified as per-
centage of all immune cells, there were significant decreases of
CD8+ T cells, NK cells, B cells and tumor-associated macro-
phages (TAMs), yet there was a dramatic increase from ~1% to
~50% of CD11b+ Gr1+ myeloid cells (Fig. 3b, c, and Supple-
mentary Fig. 3). We isolated the CD11b+ Gr1+ cells from
established SA tumors and demonstrated their strong ability to
suppress T cell proliferation (Fig. 3d). This result indicates that
the intratumoral CD11b+ Gr1+ cells belong to myeloid-derived
suppressor cells (MDSCs) that have been recognized as a major
immunosuppressive population to induce T cell tolerance in solid
tumors. Recent work from others and us indicated that PI3K
signaling is crucial to mediate the immunosuppressive activity of
myeloid cells31–33. In accordance with this notion, viSNE analysis
of the CyTOF data showed stronger phospho-PI3K, phospho-
mTOR and phospho-S6 signals in the CD11b+ Gr1+ population
compared with other immune cells (Fig. 3c). This result suggests
that targeting PI3K signaling may be an effective approach to
attenuate MDSC activities in the mouse PSCC and restore the
response to immune checkpoint blockade (ICB) therapy. Given
that the infiltrating T cells in the SA tumors are positive for PD1
(Fig. 3e), it is rational to test whether co-targeting MDSCs
synergizes with the ICB therapy.
Combining targeted therapy and immunotherapy. To examine
the efficacy of ICB in the SA model, we randomized SA males with
established PSCC at 4–5 month old to receive isotype IgG (control)
or an anti-PD1/anti-CTLA4 antibody cocktail (ICB) at doses
described recently31. The treatment lasted for one month and
affected minimally on tumor weight (Fig. 4a, b). To enhance ICB,
we focused on two FDA-approved drugs, cabozantinib and cel-
ecoxib. Cabozantinib is a multi-targeted tyrosine kinase inhibitor
and recently shown to block PI3K signaling in MDSCs to enable
efficacy from ICB in metastatic prostate cancer31. Celecoxib is a
selective COX2 inhibitor and highly relevant to our study, because
Cox2 was upregulated in the SA tumors (Fig. 2e) and identified as
the top putative master regulator for inflammation-related phe-
notypes (Fig. 2f). Cyclooxygenase-dependent tumor immune eva-
sion is through myeloid cell reprograming and Cox2 blockade with
celecoxib synergizes with anti-PD1 or dendritic cell immunother-
apy in syngeneic models of a few cancer types34,35.
While the targeted therapy drugs, similar to ICB alone, caused
marginal effect on penile tumor progression and endpoint weight,
the combinations (cabozantinib plus ICB, celecoxib plus ICB) led
to eradiation of most tumor nodules (Fig. 4a, b). At the cellular
level, cabozantinib or celecoxib was sufficient to significantly
reduce the infiltration of myeloid cells positive for CD11b (Fig. 4c
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and Supplementary Fig. 4a) and Ly6G (Fig. 4d, e), consistent with
the reported effect from these drugs. On the other hand, ICB
potently decreased the number of Foxp3+ regulatory T cells
(Tregs) in the tumors (Fig. 4f and Supplementary Fig. 4b).
Cabozantinib plus ICB, or celecoxib plus ICB treatment led to
simultaneous reduction of both myeloid cells and Tregs (Fig. 4c, d,
and f), explaining the synergistic efficacy. Our results demonstrate
that the SA model can serve as the platform to discover
combination strategies for immunotherapy of spontaneous PSCC.
Pten deletion confers resistance to cisplatin. PI3K/Akt/mTOR
pathway is relevant to both HPV-positive and HPV-negative
PSCC. Infection by HPV 16, the most common high-risk HPV
type in PSCC, induces PI3K/Akt/mTOR pathway which plays a
critical role mediating the cellular entry of the virus36. Clinically,
PIK3CA mutation is found to happen in 29% of PSCC cases37,
and PTEN expression loss and PI3K/Akt/mTOR pathway acti-
vation is common in PSCC independently of HPV infection38,39.
These findings prompted us to cross the SA mice with the con-
ditional null allele of Pten to generate the PB-Cre4+ Smad4L/L
ApcL/L PtenL/L mice (SAP genotype). Homozygous, but not het-
erozygous, loss of Pten dramatically accelerated the formation of
penile tumors (Fig. 5a). Median prolapse survival was 17.2 weeks
and 8.1 weeks for SA and SAP mice, respectively. As expected,
Pten loss in the penis augmented the phospho-Akt signals, shown
in PB-Cre4+ PtenL/L mice and more pronounced in the SAP mice
(Fig. 5b). In contrast to the SA model, the SAP mice co-develop
highly aggressive prostate tumors at a similar timeframe as the
penile tumors. To address the question whether PSCC forms in
SAP mice independently of the prostate tumors, we took two
approaches. First, we performed radical prostatectomy on SAP
male at 8 weeks of age and followed the penile tumor progression
for 3 more weeks (Fig. 5c). Without the prostate, SAP penile
tumors continued to grow and at the endpoint stained strongly
with Ki67 and weakly with cleaved caspase-3 (Fig. 5d). Second,
we established a PSCC cell line SAP1 from the SAP model and
orthotopically injected into the penile and prostate tissues indi-
vidually or simultaneously to evaluate whether orthotopic penile
tumor growth was affected by orthotopic prostate tumors. The
result showed robust injection-site-dependent orthotopic tumor
formation (Fig. 5e) and the orthotopic penile tumors remained
salient SCC features such as keratin pearl and positivity for
cytokeratin-5 (Fig. 5f). Orthotopic injection of SA1 (the cell line
derived from SA tumors) also generated PSCC, albeit with a
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longer latency (Supplementary Fig. 5a). Therefore, these data rule
out that the PSCC formed in the SAP model is due to distant
effects or metastasis from the concomitantly formed prostate
tumors.
There are four general modes of resistance mechanisms for
cisplatin40, and PI3K/Akt activation stands as an important post-
target mechanism41,42. To evaluate the effect of Pten deletion on
cisplatin response in penile cancer, we subjected SA and SAP
mice with established penile tumors to cisplatin dosed at 10 mg/
kg weekly for a month. Cisplatin generated potent anti-tumor
effect for SA mice, but affected SAP tumors minimally (Fig. 5g,
h). This anti-tumor effect on SA but not SAP models was likely
the result of distinct sensitivity of the two models to cisplatin-
induced apoptosis (Supplementary Fig. 5b). Overall, the SAP
model provides an essential tool to study cisplatin resistance.
Targeted proteomics profiling and drug screen. Reverse-phase
protein arrays (RPPA) is a technology for high-throughput pro-
tein activity measurement across many signaling pathways
involved in cancer43. We performed RPPA profiling and observed
a genotype-correlated protein expression pattern (Fig. 6a and
Supplementary Table 7). Penises from wild type mice clustered
together with those from PB-Cre+ ApcL/L and PB-Cre+ PtenL/L
mice (no tumors), whereas SA and SAP tumors clustered in
separate branches. Effect from cisplatin treatment (Fig. 5c) was
notable by the separation of treated tumor from untreated tumors
in both genotypes. Despite the separation of SA and SAP samples
in the clustering, there was a large overlap of differentially
expressed protein species in SA and SAP tumors compared with
WT penises (Fig. 6b and Supplementary Table 8). Most of the
overlapped proteins were up- or down-regulated in the same
a b
c
e
d f
0.6
Control
ICB
ICB +
Cabozatinib
ICB +
Celecoxib
ICB
ICB +
Cabozatinib
ICB +
Celecoxib
Start
point
End
point
Start
point
End
point
#
#
# #
#
#
0.4
P
en
is
 w
ei
gh
t (
g)
C
D
11
b+
 c
el
ls
/fi
el
d
0.2
0.0
200
CD11b Ly6G Foxp3
150
100
50
0
Ly
6G
+
 c
el
ls
/fi
el
d
F
ox
p3
+
 c
el
ls
/fi
el
d
150 80
60
40
20
0
100
50
0
Co
nt
ro
l
Ca
bo
za
nt
ini
b
Cabozantinib
Ce
lec
ox
ib
Celecoxib
Control
Ly
6G
 IH
C
Cabozantinib Celecoxib
IC
B
IC
B 
+ 
Ce
lec
ox
ib
IC
B 
+ 
Ca
bo
za
nt
ini
b
Co
nt
ro
l
Ca
bo
za
nt
ini
b
Ce
lec
ox
ib
IC
B
IC
B 
+ 
Ce
lec
ox
ib
IC
B 
+ 
Ca
bo
za
nt
ini
b
Co
nt
ro
l
Ca
bo
za
nt
ini
b
Ce
lec
ox
ib
IC
B
IC
B 
+ 
Ce
lec
ox
ib
IC
B 
+ 
Ca
bo
za
nt
ini
b
Co
nt
ro
l
Ca
bo
za
nt
ini
b
Ce
lec
ox
ib
IC
B
IC
B 
+ 
Ce
lec
ox
ib
IC
B 
+ 
Ca
bo
za
nt
ini
b
Fig. 4 Combined targeted therapy and immunotherapy for spontaneous PSCC in mice. a Weight of resected penis from SA mice at the endpoint of the
treatment course with single or combination therapies (n= 6, 3, 5, 3, 3, and 4, respectively). b Representative images of penises for the SA mice before and
after the 1-month treatment course. c, d Quantification of IHC staining for CD11b and Ly6G, markers of tumor infiltrating granulocytic MDSCs, using SA
tumor samples treated differently (independent IHC images for CD11b: n= 4, 5, 4, 9, 4, and 4, respectively; independent IHC images for Ly6G: n= 24, 10,
12, 12, 13, and 9, respectively). e Representative IHC images of Ly6G from the experiment in d. Scale bar 50 μm. f Quantification of IHC staining for Foxp3,
marker of Tregs, using SA tumor samples treated differently (independent IHC images: n= 11, 6, 4, 3, 8, and 6, respectively). In a, box plots visualize the
five-number summary of a data set (minimum, lower quartile, median, upper quartile and maximum). In c, d, and f, all data are shown with the line
representing the median. #P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-sided Student’s t test.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15980-9 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2124 | https://doi.org/10.1038/s41467-020-15980-9 | www.nature.com/naturecommunications 7
a b
Pe
lin
e 
Pr
ol
ap
se
 F
re
e
Cre+ Smad4L/L ApcL/L PtenL/L (n = 20)
Cre+ Smad4L/L ApcL/L (n = 36)
Cre+ Smad4L/L ApcL/L PtenL/+ (n = 28)
*
*
*
*
0 10 20 30 40
0
20
40
60
80
100
Weeks After Birth
#
0.0
0.1
0.2
0.3
0.4
0.5
Pe
ni
s 
w
ei
gh
t (g
)
**** #
SA SAP
Cisplatin ─+ ─+
g h
SAP
SA
4 cycles of Cisplatin (1 month)
Start End
10 mm 200 μm 200 μm
Bright field GFP H&E
WT Pten
SA SAP
p-Akt
p-Akt
Radical prostatectomy
Week 0
Week 1 Week 2
H&E Ki67
c
AP
DLP
VP
CC3d
e
f
Bright field H&E Cytokeratin-5
Prostate
Penis 10 mm
Prostate
Penis
Prostate
Penis
SA
P1
Penis Prostate
0.0
0.1
0.2
0.3
0.4
0.5
W
ei
gh
t (g
)
Penis
Penis + prostate
Prostate
****
**
**
SAP1cell line
orthotopically injected to:
#
#Week 3
Fig. 5 SAP mice as a model to study chemoresistance of penile cancer. a Penile prolapse free survival curves for mice of three genotypes with n indicated.
****P < 0.0001, #P > 0.05, log-rank test. b Representative IHC images of phospho-Akt (Ser473). Scale bar 100 μm. c SAP mouse at 8 weeks old with all
prostate lobes removed (anterior AP, dorsolateral DLP, ventral VP) and penile tumor followed for 3 weeks before sacrifice. d Representative H&E and IHC
images of Ki67 and cleaved caspase-3 (CC3) of the penile tumor from the prostate-removed SAP mouse (n= 3). Scale bar 200 μm. e Orthotopic injection
of SAP1 cells under the penile epithelium, or into the prostate gland or at both sites of 6-week Rag1−/− males (n= 5). The mice were euthanized at Day 30
post-injection for organ weight measurement and imaging. Scale bar 10 mm. (f) Representative penile tumor formed by penile injection of SAP1 with H&E
staining and IHC of cytokeratin-5 (n= 5). Scale bar 10mm and 200 μm. g Weight of resected penis from SA and SAP mice at the endpoint of cisplatin
treatment course (n= 4 for each group). h Representative images and H&E staining of penises for the SA and SAP mice before and after the 1-month
cisplatin treatment. Scale bars 5 mm (bright field and GFP); 1 mm (H&E). In e, g, box plots visualize the five-number summary of a data set (minimum,
lower quartile, median, upper quartile and maximum). #P < 0.05, **P < 0.01, ****P < 0.0001, two-sided Student’s t test.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15980-9
8 NATURE COMMUNICATIONS |         (2020) 11:2124 | https://doi.org/10.1038/s41467-020-15980-9 | www.nature.com/naturecommunications
direction in the two genotypes, with the exception of phospho-
Akt (S473) which was upregulated in SAP tumors but down-
regulated in SA tumors (Fig. 6b). Among the commonly upre-
gulated proteins in SA and SAP tumors, proteins involved in
metabolic regulation, cell motility and morphology, cell cycle and
stemness were notable (Fig. 6c). Interestingly, p16INK4a, whose
overexpression is often found correlated with high-risk HPV
infection44, was upregulated in both SA and SAP tumors (Fig. 6c
and Supplementary Fig. 6a). The alternative product p19ARF (not
included in RPPA) from the INK4a locus was also upregulated in
both tumors (Supplementary Fig. 6a). Another drastically over-
expressed protein, CDH3 (i.e. P-Cadherin), was confirmed by
IHC (Supplementary Fig. 6b). Among the commonly under-
expressed proteins (Fig. 6d), AR was notable because of similar
trend observed in clinical PSCC (Fig. 1a). AR downregulation and
exclusion from nucleus in SA and SAP tumors was evident by
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IHC analysis (Supplementary Fig. 6c), consistent with our result
showing AR signaling is dispensable for sustaining PSCC pro-
gression (Fig. 1i-l). Using signals from the phospho-specific and
total Akt antibodies, the calculated pS473/total-Akt ratio showed
significant increase in SAP but not SA tumors (Fig. 6e). This
result was validated by western blot (Fig. 6e) and consistent with
Pten-loss induced PI3K/Akt pathway activation in SAP tumors.
Overexpressed proteins in SA and SAP tumors provide the
opportunity for the identification of potential therapeutic targets.
We established 3 SA cell lines (SA1, SA2, SA3) and 2 SAP cell lines
(SAP1, SAP2) from the two tumor models respectively. Compared
with the tumor issues which contain heterogeneous cell popula-
tions, these cell lines showed cleaner pattern of respective gene
knockouts (Supplementary Fig. 6d, e). We used SA1 and SAP1 cell
lines to perform a 42-compound dose titration assays with small
molecules that target the overexpressed proteins and related
pathways (Supplementary Table 9). These cells showed medium
to high sensitivity to 31 drugs (IC50 < 100 μM for both lines), with
SAP1 cells displaying comparable or higher IC50 for most drugs
except for mubritinib (Fig. 6f). In the validation assays, we
confirmed the high sensitivity of both SA1 and SAP1 cells to
staurosporine, a potent protein kinase C inhibitor with anti-tumor
activity and low toxicity in a liposomally encapsulated form in
preclinical models45. The higher sensitivity of SAP1 to mubritinib
relative to SA1 (Fig. 6h) is likely due to the on-target effect on the
active HER2 signaling in SAP tumors (Fig. 6i), because mubritinib
is a selective HER2 tyrosine kinase inhibitor46. Together, the SA1
and SAP1 cell lines, in conjunction with the GEM models, provide
the in vitro and in vivo models to develop therapeutic strategies for
the treatment of lethal PSCC.
Expression convergence of human and mouse PSCC. In order
to determine if the spontaneous PSCC developed in SA and SAP
mice resemble human PSCC at the molecular level, we compared
the top 200 up- and down-regulated genes in human penile
cancer47 with the mouse transcriptomic data. For the 172 out of
the 200 human genes that have the mouse homologs, 108 (63%)
and 89 (52%) showed significant difference in SAP and SA
models, respectively (Fig. 7a and Supplementary Table 10),
demonstrating significant convergence of gene expression pat-
tern. IPA analysis of the Kuasne dataset identified several highly
enriched pathways that were also enriched in SA tumors, in
particular immune-related pathways such as Agranulocyte
Adhesion and Diapedesis (P= 7.1 × 10−9), Leukocyte Extra-
vasation Signaling (P= 0.003) and Eicosanoid Signaling (P=
0.03) (Supplementary Table 11). Wnt/β-catenin Signaling was
also highly enriched (Supplementary Fig. 7, P= 0.001), consistent
with the enhanced cytoplasmic and nuclear β-catenin level
(Supplementary Fig. 2c). IPA identified potential upstream reg-
ulators that explain the transcriptional changes of human penile
cancer, which included activated targets by pro-inflammatory
factors such as TNF, CSF2, IFNγ, IL1B, and inhibited targets by
TGFβ1 (Supplementary Table 12). Interestingly, cytokines (IL1A,
IL1B, TNF, CXCL1, CCL20) and MMPs (MMP7, 9, 10, 12, 13),
upregulated in both human and mouse PSCC, showed no cor-
relation with HPV status (Fig. 7b). The strongly expressed
inflammatory genes in both human and mouse PSCC prompted
us to examine the immune cell markers in human penile cancer
tissues. Compared with adjacent normal penile compartment, the
malignant tissue was infiltrated extensively with T cells (CD3+)
including the CTL subset (CD8+), as well as macrophages (CD68
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+) (Fig. 7c). Recent reports showed frequent PD-L1 upregulation
in PSCC48, which was confirmed in our small cohort (Fig. 7c).
We also validated that SOX2 and COX2 were upregulated in
human PSCC (Fig. 7c). Together, the resemblance of murine
PSCC model with human PSCC underscores the clinical rele-
vance of the mouse model.
Discussion
Our studies build essential resources for translational research in
penile cancer. The GEM model of PSCC in our studies is based on
the use of PB-Cre4 as the Cre driver in AR-expressed androgen-
responsive epithelial cells of the mouse penis. Androgen-AR
signaling has a fundamental role in masculinization during
development, initiating formation of the prostate, penis and tis-
sues of the male reproductive tract49. Transcriptional activity of
AR is essential for normal penile growth, as inhibition of
androgen in the neonatal phase induces micropenis in mice50.
Our models indicate that the androgen-sensitive epithelial cells
are the potential cells of origin for PSCC, although AR expression
is unlikely to be essential for sustaining tumorigenesis based on its
diminished level in established PSCC (Fig. 1a). Given the variety
of tumor suppressor genes and oncogenes manipulated to model
prostate cancer using the PB-Cre4 driver, it is remarkable that
concurrent inactivation of Smad4 and Apc were the only reported
genetic changes sufficient to drive oncogenesis of mouse penile
epithelium. APC loss and WNT pathway activation may also play
a key tumorigenic role in human PSCC. Inactivation of APC
through mutation, promoter methylation, and loss of hetero-
zygosity is frequent in oral SCC51–53. WNT ligand and β-catenin
downstream targets (WNT4, MMP7, CCND1, MYC) were found
upregulated in PSCC54. It is worth noting that activation of
WNT/β-catenin targets may be achieved through various
mechanisms. For example, loss of function of FAT1, caused by
recurrent somatic mutations in various cancer types, leads to β-
catenin nuclear localization and transcriptional activation of
WNT downstream targets55. FAT1 mutation occurs in about 15%
of penile cancer56 and may account for β-catenin activation in
penile cancer. In the backdrop of Apc deletion, removal of the
tumor suppressive function of TGFβ/SMAD (through Smad4
deletion) and installation of the tumor promoting function of
PI3K/AKT/mTOR (through Pten deletion) independently pro-
motes the formation of SCC of the mouse penis. In fact, Smad4
knockout in head and neck epithelia of mice led to development
of head and neck SCC57, which together with our results suggest
the general role of Smad4 as a gatekeeper gene for SCC. We like
to note that our model should raise a concern to the many
investigators who use PB-Cre4 to model prostate diseases like
prostate cancer. Since this Cre driver is active in penile epithe-
lium, attention should be made to whether the prostate pheno-
type might be influenced by the potentially concurrent phenotype
of the penile tissue.
Among the large number of downstream targets of β-catenin
activation, we focused on Sox2 and Cox2, both of which are
relevant to PSCC. SOX2 is frequently amplified in SCC, including
32% of penile tumors58. PSCC tissues express high level of COX2,
PGE2 and EP receptors28. SOX2 and COX2 may function as the
master regulators to orchestrate intrinsic and extrinsic mechan-
isms of penile malignancy in the mouse model, in a similar
manner as the cooperation of Sox2 and inflammation-inducing
Stat3 to transform foregut basal progenitor cells59. The essential
role of Sox2 in controlling the self-renewal of tumor-initiating
cells in SCC have been shown in the skin, head and neck, and
lung27,60,61. In Apc-deficient PSCC, Sox2 may collaborate with β-
catenin to regulate the pro-tumor transcriptome, such as upre-
gulation of cyclin D1 as shown previously in breast cancer62. We
have shown that Sox2 knockdown attenuated mouse PSCC
growth (Fig. 2i–l). Future studies will uncover precise mechan-
isms of Sox2 in PSCC. The most striking feature of the infiltrating
immunoprofile of the SA tumors is the massive CD11b+ Gr1+
MDSCs, which may result from the induction by COX2-mediated
PGE2 production in the milieu, a phenomenon observed in both
murine and human MDSCs63–65. The vulnerability of MDSCs to
the inhibition of induction signals (e.g. COX2-prostaglandins)
and survival signals (e.g. PI3K) provides opportunities to block
these cells and foster a more hospitable environment for immu-
notherapy to work, as we demonstrated in the SA models (Fig. 4).
The rationale to treat metastatic PSCC with ICB certainly
exists, with especially anti-PD-1 or anti-PD-L1 therapies66. PD-
L1 is detected in 40–60% of PSCC cases and is correlated with
poor prognosis and the number of tumor-infiltrating lympho-
cytes48. In a case report, a patient with an HPV-negative PSCC
treated with nivolumab experienced a partial response67. Cur-
rently, there are multiple ICB trials recruiting patients with
PSCC (e.g. NCT02837042, NCT02721732, NCT03333616,
NCT02834013, and NCT03391479). Our data suggest that better
response may be achieved when ICB is combined with targeted
therapeutics that eliminates activity from immunosuppressive
cells. In a recent Phase I clinical trial on metastatic genitourinary
malignancy using cabozantinib with nivolumab and ipilimumab
(NCT02496208), manageable toxicity and promising antitumor
activity was observed, including partial response for two out four
PSCC patients68. An important question is whether HPV status
should be a criterion for enlisting PSCC patients in ICB trials.
Given that PD-L1 expression in PSCC is not correlated with
HPV infection48, together with the observed inflammatory gene
signature in both HPV-positive and negative clinical PSCC
samples (Fig. 7b), we argue for the concept of treating both
HPV-positive and negative PSCC with combined ICB and
MDSC-inhibiting drugs.
The PSCC resources developed in our studies include two
GEM models and related murine PSCC cell lines. The applica-
tions of these reagents could have an impact on developing
effective targeted therapy and immunotherapeutic approaches for
patients with PSCC in addition to defining pathways of resistance.
Methods
Animals. All animal works performed in this study were approved by The Uni-
versity of Texas MD Anderson Cancer Center Institutional Animal Care and Use
Committee and The University of Notre Dame Institutional Animal Care and Use
Committee. Acquisition and maintenance of the genetic alleles PB-Cre4, PtenL/L,
Smad4L/L, mTmGL/L and ApcL/L were recently described in our studies31,69. C57BL/
6 and Rag1 knockout were purchased from Jackson Laboratories (stock# 000664
and 003145, respectively). NCr nude mice were purchased from Taconic (stock#
NCRNU-M). Since penile cancer is a male disease, all the experimental cohorts
used male mice. The mice were maintained in 12 h/12 h light/dark with an ambient
temperature of 72 oF and humidity of 35%. All animals were maintained in
pathogen-free conditions and cared for in accordance with the International
Association for Assessment and Accreditation of Laboratory Animal Care (AAA-
LAC) policies and certification.
Cell culture. Lentivirus packaging cell line 293T (ATCC, CRL-3216) was cultured
in DMEM, 10% fetal bovine serum (FBS), 100 U/mL (1x) Penicillin-Streptomycin.
Murine penile cancer cell lines SA1, SA2, SA3, SAP1 and SAP2 were established
from individual established SA and SAP penile tumors. All the cells were cultured
in DMEM, 10% fetal bovine serum (FBS), 100 U/mL (1x) Penicillin-Streptomycin.
The cell lines were of the male gender and confirmed free of mycoplasma with
MycoAlert Mycoplasma Detection Kit (Lonza).
Clinical samples. The eight patient specimen cohort (see Supplementary Table 1)
was retrieved from banked archival tissue specimens among patients who had
previously consented to have their incidental specimens banked for future research
at the University of Texas M.D. Anderson Cancer Center utilizing an approved
protocol. Specific blocks were selected based upon the abundance of tissue for
additional studies (i.e., usually tumors greater than 1 cm in size) and the patients
were further characterized with respect to age, clinical stage, grade, histology, type
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of surgery, and Human papillomavirus status. De-identified specimens were pro-
vided to the research team under an institutional protocol (PA15-0138) for further
characterization under waiver of consent.
Histology, tissue array, immunostaining, and western blot. Tissues were fixed
in 10% formalin overnight and embedded in paraffin. Hematoxylin & eosin
staining was performed using standard protocols on 5 μm paraffin sections. His-
tologic evaluation of H&E stained sections of mouse penile tumors was performed
by two urological pathologists (P.T. & P.R.).
For immunohistochemistry (IHC), 5 μm paraffin sections were deparaffinized,
followed by pressure cooker boiling in antigen retrieval solution (10 mM sodium
citrate, pH= 6). Subsequent steps followed manual instructions of VECTASTAIN
Elite ABC-HRP Kit (Vector Laboratories) with DAB substrate (Vector
Laboratories). Primary antibodies are listed in Key Resources Table. IHC slides
were scanned with Pannoramic Digital Slide Scanner (3DHISTECH) and images
were cropped from virtual slides in Pannoramic Viewer. For tissue array studies of
β-catenin IHC of human normal penile tissue and PSCC, we used two
commercially available tissue arrays, PE241 and PE2081, from US Biomax, Inc.
PE241 had 20 PSCC cases and PE2081 had 174 PSCC cases (3 had no tissues).
Together these two arrays had seven adjacent normal tissues. The tissue array slides
were deparaffinized and stained with β-catenin antibody (Cell Signaling
Technology).
For immunofluorescence (IF) staining, tissues were harvested freshly and
cryopreserved in Optimal Cutting Temperature (OCT) Compound. Cryosections
were blocked in 5% normal goat serum (Vector Laboratories), and incubated with
primary antibodies (see Key Resources Table) overnight at 4 °C. Samples were then
incubated with secondary antibodies conjugated with Alexa Fluor 488 or Alexa
Fluor 568 (Invitrogen) at RT for 1 h. Slides were mounted with VECTASHIELD
mounting medium with DAPI (Vector Laboratories). Stained slides were imaged
using Nikon A1R Confocal Laser Microscope and images were managed with
ImageJ software.
For western blot, fresh tissues were soaked in ice-cold RIPA buffer (Boston
BioProducts) supplemented with protease and phosphatase inhibitors (Roche), and
homogenized with Fisherbrand 150 Handheld Homogenizer. Samples were
centrifugation at 15,000×g for 10 min at 4 °C. Proteins were resolved by
SDS–PAGE, transferred to nitrocellulose membrane and analyzed by immunoblot
using primary antibodies listed in the Key Resources table. Anti-rabbit or anti-
mouse IgG conjugated to horseradish peroxidase (Cell Signaling Technology) were
used as secondary antibodies. Detection was performed with Clarity Max Western
ECL Substrate (Bio-Rad) followed by exposure to Amersham ECL Hyperfilm (GE
Healthcare).
Reverse phase protein array. Reverse phase protein array (RPPA) experiment
was performed at the RPPA core at MD Anderson Cancer Center. Total 27 freshly
dissected mouse penile normal or tumor samples were probed with 299 antibodies.
Briefly, tumor lysates were serially diluted two-fold for 5 dilutions (from undiluted
to 1:16 dilution) and arrayed on nitrocellulose-coated slides in an 11 × 11 format.
Samples were probed with antibodies by tyramide-based signal amplification
approach and visualized by DAB colorimetric reaction. Slides were scanned on a
flatbed scanner to produce 16-bit tiff image. Spots from tiff images were identified
and the density was quantified by Array-Pro Analyzer. Relative protein levels for
each sample were determined by interpolation of each dilution curves from the
standard curve (supercurve) of the slide (antibody). These values (given as Log2
values) are defined as Supercurve Log2 (Raw) values. All the data points were
normalized for protein loading and transformed to linear value and used for bar
graphs. The antibody list, including vendor and catalog information, can be found
on the website of the RPPA core at MD Anderson Cancer Center. For hierarchical
clustering, normalized signals generated from rabbit and goat antibodies were
analyzed using one-way ANOVA (alpha 0.05), and the resulted 117 significant
proteins were clustered using average lineage method with Pearson correlation.
Mass cytometry (CyTOF). The procedure for antibody staining and gating
strategy was described as following70. Briefly, single cells from mouse penile tumors
were prepared using the Mouse Tumor Dissociation kit (Miltenyl Biotec). All
isolated cells were depleted of erythrocytes by hypotonic lysis, and blocked for
FcγR using CD16/CD32 antibody (clone 2.4G2, BD Biosciences) and incubated
with metal-conjugated antibodies targeting cell surface antigens for 30 minutes at
room temperature. Cells were washed and incubated with 5 μM Cell-ID Cisplatin-
195Pt (Fluidigm) for 3 min for viability staining. Cells were washed and fixed
following the steps of the Foxp3/Transcription Factor Staining Buffer Set
(eBioscience). Fixed cells were stained with metal-conjugated antibodies targeting
intracellular antigens for 1 hour at room temperature. Cells were washed and
incubated with Nucleic Acid Intercalator-Ir (Fluidigm) at 4oC overnight to stain all
the nuclei. The samples were analyzed with CyTOF instrument (Fluidigm) in the
Flow Cytometry and Cellular Imaging Core Facility at MD Anderson Cancer
Center. CyTOF data were analyzed and visualized using Cytobank (http://www.
cytobank.org).
Therapeutic treatment in SA model. SA mice develop spontaneous penile
tumors. Therefore, the mice were monitored daily for penile prolapse phenotype
and, once the tumors reached 2–3 mm in diameter, the mice were randomly
assigned to one of the treatment arms of a preclinical trial. Cabozantinib (Selleck
Chemicals, S1119) and celecoxib (LC Laboratories, C-1502) were orally adminis-
tered at daily doses of 30 mg/kg and 200 mg/kg, respectively, daily on a Monday
through Friday schedule. Anti-PD1 (clone RMP1-14, BioXcell, BE0146) and anti-
CTLA4 (clone 9H10, BioXcell, BE0131) antibodies (or their respective isotype IgG
controls) were intraperitoneally administered at 200 μg/injection three times/week.
Cisplatin was intraperitoneally injected weekly at 10 mg/kg (equivalent to 40 mg/
m2 in human). The duration of drug treatment was 4 weeks. At the endpoint, the
penis from each treated mouse was resected and weighed, then fixed in formalin for
histological analysis.
Gene expression profiling and analysis. Three 5-month-old SA mice were used
for harvesting penile tumors. Age-matched WT (wild type) C57BL/6 mice were
used for harvesting normal penile epithelium. Total RNA from fresh tissues was
extracted using Direct-zol RNA Miniprep Kit (Zymo Research). The quantity and
quality of each sample were measured using an Agilent 2100 Bioanalyzer. RNA
sequencing was performed at Sequencing and Microarray Facility at MD Anderson
Cancer Center using standard stranded RNA-seq protocol on an Illumina HiSeq
4000 (20 million pair-end sequence reads per sample).
The raw reads were aligned to the mouse reference genome build mm10, using
Tophat RNASeq alignment software. The aligned reads were verified for quality
using FASTQC software. HTseq software was used to summarize the gene
expression counts from Tophat alignment data after sorting the BAM files. The raw
counts were normalized and differential expression analysis was performed using
the DEseq2 package. Cluster analysis was performed with the log transformed
normalized count Data. Heatmaps were used to depict the clustering and
differential expression analysis results. Significant genes were defined by using a
cut-off of 0.01 on the BH corrected P-value and an absolute log2(fold change) value
of at least 2. Pathway analysis and upstream regulator analysis were performed with
Ingenuity Pathway Analysis (QIAGEN). The raw and normalized data files are
deposited by Basepair Tech to Gene Expression Omnibus (GEO) with series entry
number GSE130052.
To examine if the differentially expressed genes between mouse penile tumor
and normal penile epithelium were also dysregulated in human penile cancer
samples, we downloaded published transcriptomic dataset of human penile cancer
GSE5795547 and identified the top 200 up- and down-regulated genes. Among
these 200 genes, 172 have mouse homolog genes. Among these 172 genes, 108
(63%) and 89 (52%) genes showed significant difference in SAP and SA models
(penile tumor compared with normal mouse penis in the RNA-seq data),
respectively. The results were displayed as a clustering heatmap (Fig. 7a). For a
number of selected genes, human and mouse gene RNA levels (normalized to
normal penile tissues) were plotted to demonstrate consistent cross-species
upregulation of these genes (Fig. 7b).
T cell proliferation assay and suppression by MDSC coculture. Briefly, to
isolate MDSCs from SA penile tumors, tumors were harvest and digested by Mouse
Tumor Dissociation kit (Miltenyi Biotec) to obtain the single cells. Total MDSCs
were isolated using Mouse Myeloid-Derived Suppressor Cell Isolation Kit (Miltenyi
Biotec). Total spleen T cells were isolated from spleen of 2-month-old male C57BL/
6 mice (Jackson Laboratory) using the mouse Pan T Cell Isolation Kit II (Miltenyi
Biotec). To assess the suppressive activities of MDSCs on T cell proliferation, we
first labeled the T cells with 5 μM carboxyfluorescein diacetate succinimidyl ester
(CFSE) (Invitrogen). The labeled T cells were stimulated in an antigen-nonspecific
manner with anti-CD3 and anti-CD28 antibodies following eBioscience’s protocol.
MDSCs were added at different ratios to T cells. CFSE intensity was quantified 72 h
later with BD LSRFortessa Cell Analyzer. Viable CD3+ T cells with CFSE peaks
located left of the highest peak (i.e. no proliferation, thus no decline of CFSE
intensity) were counted as CFSElow (i.e. proliferative) cells.
Sox2 knockdown and in vivo experiments. To knockdown Sox2 with shRNA,
scramble control SHC202 or Sox2-specific shRNA (Sigma-Aldrich, TRCN0000416106
as #2, TRCN0000420955 as #3) lentiviruses were packaged with 293T cells and used to
infect SA1 cell line to generate puromycin-resistant stable sublines. The knockdown
was confirmed by western blot. For in vivo tumorigenesis, 1 × 106 cells in 100 μl PBS
were injected subcutaneously in the dorsal skin of male 6-week-old NCr nude mice.
Tumor dimensions were measured with a digital caliper and tumor volume was
determined as 1/2 (length × width2). The mice were euthanized at the experimental
endpoint, and tumors were dissected, weighted and photographed.
Inhibitor screening using mouse penile cancer cell lines. Inhibitors were pre-
pared as 10 mM stock in DMSO or water according to manufacturer’s instructions.
SA1 and SAP1 cell lines were seeded at 104 cells/well in 96-well plates in the
absence or presence of inhibitors at 0.2, 2.0, and 20 μM in triplicates. In all, 48 h
later, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
was added to the wells at final concentration of 0.5 mg/ml. The plates were gently
shaken at 500 rpm for 1 min, and incubated at 37 °C for 4 h. The medium was
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removed completely, and 100 μl DMSO was added into each well. The plates were
gently shaken at 1000 rpm for 5 min to mix well the colored solution, and placed to
microplate reader (Epoch 2, BioTek) to read 540 nm and 690 nm (reference). A
confirmative second round of MTT assay was performed with a more refined range
of inhibitor concentrations to determine IC50 more precisely.
Penile orthotopic injection. Male Rag1 knockout males are anesthetized by
inhalation of 2% isoflurane, then placed on the back with arms and legs extended.
The urogenital region is prepared for surgery with alcohol swab. Sterile insulin
syringe with 30-gauge needle is loaded with 50 μl of 1 × 106 mouse penile cancer
cells. With one hand keeping the glans penis stretched, from the ventral side of the
glans penis, the other hand aims the needle to the superficial epithelial spine layer
and keeps the bevel parallel with the glans axis so that the needle does not penetrate
the glans. Cells are slowly injected with the formation of a small bump at the
injection site as the indication of successful injection.
Radical prostatectomy. Anesthetized mouse is placed on its back with arms and
legs extended. An operating stereomicroscope is used for the entire surgery. Access
to the pelvis is via a median abdominal incision (2.5 cm). The prostate ventral lobes
and dorsolateral lobes are bluntly separated from the urethra using a cotton swab.
The anterior prostate is dissected using the seminal vesicles as landmarks, and the
prostate is then detached from the dorsal urethra.
Surgical castration. The mouse was anesthetized and both testes of the mouse
were pushed down into the scrotal sacs, followed by ~1 cm incision through the
skin along the midline of the scrotal sac. Then a 5 mm incision was made in the
membrane on one side of the midline. The testis was pushed out, dissected away
from the fat pad, and removed with scissors. After that, the fat pad was pushed
back into the scrotal sac. Repeat above steps for the other testis. Buprenorphine was
used for analgesia after all surgical procedures. If it is sham-operation, there is no
removal of the testis.
Prostate orthotopic injection. The mouse was anesthetized and placed on its back
with arms and legs extended. The lower abdomen wall of the mouse was wiped
with 70% ethanol followed by betadine swab. The prostate anterior lobe was
exposed with a low midline abdominal incision about 1 cm, and 30-gauge needle
was used to inject of 5 × 105 cells in 50 μl PBS. The prostate was returned to the
peritoneum. Buprenorphine was used for analgesia after all surgical procedures.
Statistics and reproducibility. Data were presented as mean ± standard deviation
(SD) unless indicated otherwise. Number of biological samples (n) for the
experiments was denoted in figure legends. Results showing representative
experiments (such as micrographs) were repeated independently at least three
times with similar results. Unless indicated otherwise, two-sided Student’s t test
assuming two-tailed distributions was used to calculate statistical significance
between groups (no assumption was made that variance was similar between the
groups that are being statistically compared). P < 0.05 was considered statistically
significant. Data analysis was assisted with Graphpad Prism version 7, Cytobank
6.3.1, R version 3.3.3, and Ingenuity Pathway Analysis (QIAGEN).
Reagents and resources. All the reagents and resources used and generated in
this study are listed in Supplementary Table 13.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The RNAseq data generated in the study have been deposited and available for public
access in the Gene Expression Omnibus (GEO) database under the accession code
GSE130052. The GSE57955 data referenced during the study are available in a public
repository from the GEO website. All the other data supporting the findings of this study
are available within the article and its supplementary information files and from the
corresponding author upon reasonable request. A reporting summary for this article is
available as a Supplementary Information file.
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